Immuno-Oncology | Specialty

Nivolumab, Pembrolizumab Compete for Top Choice in NSCLC Treatment

March 8th 2016

Benjamin Levy, MD, discusses how nivolumab and pembrolizumab have impacted the treatment landscape of NSCLC, how to choose between the two for patients, and what biomarkers are in development for PD-1/PD-L1 agents.

FDA Accepts Application to Expand Pembrolizumab NSCLC Indication

March 7th 2016

The FDA has accepted a supplemental new drug application for pembrolizumab as a treatment for patients with advanced non–small cell lung cancer with PD-L1 expression on ≥1% of tumors cells.

Expert Shares Challenges, Considerations When Using Immunotherapies in Melanoma

March 7th 2016

Michael Postow, MD, discusses the benefits and challenges of combination regimens versus single-agent regimens, the possibility of targeted agents with immunotherapies, and the management of toxicities with immunotherapies.

Will Immunotherapy or Targeted Therapy Take the Lead in Melanoma?

March 5th 2016

Michael Atkins, MD, discusses his views on the potential of immunotherapy versus targeted therapy in melanoma, what research has shown so far, and what could be on horizon for both classes of drugs going forward.

Dr. Belani on Impact of Nivolumab's Approval in NSCLC

March 4th 2016

Chandra P. Belani, MD, Miriam Beckner Distinguished Professor of Medicine, Penn State Milton S. Hershey Medical Center, deputy director, Penn State Hershey Cancer Institute, discusses how the FDA approval of nivolumab (Opdivo) has impacted the treatment paradigm of non–small cell lung cancer (NSCLC).

Dr. Tara C. Gangadhar on Atypical Responses with Immunotherapies in Melanoma

March 3rd 2016

Tara C. Mitchell, MD, assistant professor of Medicine at the Hospital of the University of Pennsylvania, Perelman School of Medicine, discusses atypical responses with immunotherapies in melanoma.

Dr. Randal Weber on Future Treatment Approaches for Patients With Melanoma

March 1st 2016

Randal S. Weber, MD, FACS, professor, department chair, John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses future treatment approaches for patients with melanoma.

Weber Compares BRAF/MEK, Immunotherapy Combos in Melanoma

March 1st 2016

Jeffrey S. Weber, MD, PhD, discusses recent long-term follow-up data of dabrafenib and trametinib in melanoma that may shed some light on sequencing questions for BRAF-mutated patients.

Novel Checkpoints Offer Hope After Standard Melanoma Immunotherapies Fail

February 29th 2016

Omid Hamid, MD, discusses promising agents and combinations that offer hope to patients with melanoma for whom standard checkpoint agents and/or targeted therapies are not an option.

Combination Therapy Paves the Way Forward for CTLA-4 Antibodies

February 29th 2016

New research is carving out a role for ipilimumab and a second CTLA-4-targeting drug, tremelimumab, as combination therapy with potential in a variety of solid tumors. In addition to combinations with other immune checkpoint inhibitors, the agents are being evaluated across a breadth of other strategies.

Peregrine Stops Phase III Trial of Bavituximab in NSCLC

February 26th 2016

The phase III SUNRISE trial comparing bavituximab plus docetaxel with docetaxel and placebo for patients with non–small cell lung cancer has been halted following a futility analysis.

Potential Biomarkers in Metastatic Colorectal Cancer

February 26th 2016

PI3K-Mutant Metastatic Colorectal Cancer

February 26th 2016

Microsatellite Instability Status in Colorectal Cancer

February 26th 2016

BRAF Testing in Colorectal Cancer

February 26th 2016

Pathways of Resistance in Metastatic Colorectal Cancer

February 26th 2016

Upfront EGFR Therapy in Metastatic Colorectal Cancer

February 26th 2016

EGFR Therapy as Upfront Colorectal Cancer Treatment

February 26th 2016

The Current Status of RAS Testing in Colorectal Cancer

February 26th 2016

Colorectal Cancer: Challenges in Next-Generation Sequencing

February 26th 2016